 "Venus Remedies receives patent for antibiotic Vancoplus")
The Indian Patent Office (IPO) has granted product patent for Venus Remedies Ltd's antibiotic Vancoplus. Patent licence is valid till 2025. Vancoplus is a novel antibiotic entity that is highly effective against the methicillin-resistant staphylococcus aureus (MRSA) bacterial strain and multi-drug resistant microbes primarily responsible for causing infections like meningitis, pneumonia, typhoid, septicemia, urinary tract ailments and skin diseases.
The total global market size of products used for treating MRSA-associated infections is estimated around $ 9 billion. At present, this market is growing at 4.8 percent, which is estimated to go up to 12.4 percent by 2017. In India, Vancoplus is projected to cater to a market of Rs 214 crore by 2018-19.
Venus Remedies has received patents for Vancoplus from more than 18 countries, including USA, Japan, South Africa, New Zealand, Ukraine and Australia. The company has announced that it is holding discussions with some multinational companies for the out-licencing of this product.
The total global market size of products used for treating MRSA-associated infections is estimated around $ 9 billion. At present, this market is growing at 4.8 percent, which is estimated to go up to 12.4 percent by 2017. In India, Vancoplus is projected to cater to a market of Rs 214 crore by 2018-19.
Venus Remedies has received patents for Vancoplus from more than 18 countries, including USA, Japan, South Africa, New Zealand, Ukraine and Australia. The company has announced that it is holding discussions with some multinational companies for the out-licencing of this product.